U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 36

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated May 05, 2017.	4. Expiration Date: January 31, 2026
1. Galen Hospital Alaska, Inc. dba Alaska Regional Hospital		5. Docket No.: 030-14720 Reference No.:
2. P.O. Box 143889 Anchorage, AK 99514-3189	3. License number: 50-18244-01 is amended in its entirety to read as follows:	

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.5 curies total	C. For any use permitted by 10 CFR 35.300.
D. Cesium-137 permitted by 10 CFR 35.400	D. Sealed Sources (Medi-Physics, Inc. dba GE Healthcare (formerly Amersham), Model CDC.T1 (J Series tube source))	D. 450 millicuries total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 50-18244-01

Amendment No. 36

Docket or Reference Number 030-14720

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed Sources (Bard Brachytherapy, Inc., Model STM1251; Best Medical International, Inc., Model 2300 Series; IsoAid, LLC, Model IAI-125A; Theragenics Corporation, Model AgX100; I25.S06)	E. 30 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed Sources (Best Medical International, Inc, Model 2300 Series; IsoAid, LLC, Model IAPd-103A; Theragenics Corporation, Model 200)	F. 30 millicuries total	F. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
G. Strontium-90 permitted by 10 CFR 35.400	G. Sealed Sources (GE Healthcare (formerly Amersham), Model SIA.20)	G. 90 millicuries total	G. For storage only. The medical use of this sealed source is not authorized.

CONDITIONS

10. Licensed material shall be used or stored only at the licensee's facilities located at 2801 De Barr Road, Anchorage, Alaska.

11. The Radiation Safety Officer (RSO) for this license is Peter A. Stokinger.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 50-18244-01	Docket or Reference Number 030-14720
	Amendment No. 36	

B. The following individuals are authorized users for the material and medical uses indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Bradley K. Cruz, M.D.	35.100; 35.200; 35.300
Lester B. Lewis, M.D.	35.100; 35.200; 35.300
Glenn R. Stewart, M.D.	35.300; 35.400
Richard Chung, M.D.	35.300; 35.400
Lawrence P. Wood, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Julee K. Holayter, M.D.	35.100; 35.200; 35.300
David Mills, M.D.	35.100; 35.200
Andrew Moran, M.D.	35.100; 35.200
Mark G. Poag, M.D.	35.100; 35.200; 35.300

13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

14. Sealed sources and detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 50-18244-01	Docket or Reference Number 030-14720
	Amendment No. 36	

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 31, 2005 (ML050470499)
B. Letter dated September 26, 2006 (ML070250358)
C. Letter dated August 28, 2007 (ML072820029)
D. Letter dated August 9, 2010 (ML102710598)
E. Letter dated December 8, 2016 with enclosures (ML16355A226)
F. Letter dated March 28, 2017 with enclosures (ML17100A950)
G. E-mail dated April 11, 2017 with enclosures (ML17102B285)
H. Letter dated May 5, 2017 with enclosures (ML17143A442)
I. Letter dated August 9, 2017 (ML17221A279)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 10, 2017

By: **R/A**

Michelle M. Hammond
Region IV